Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.52 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.52 |
| ▸ | TERT | O14746 | 2/20 | 0.51 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ESR1 | P03372 | 3/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | IP6K2 | Q9UHH9 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21801158 | 0.84 | CYP1A2 (0.57) | CSNK2A2CSNK2BCSNK2A1CYP1A1CYP1A2 | |
| SCHEMBL15231415 | 0.82 | CSNK2A2 (0.65) | CSNK2A2CSNK2BCSNK2A1TERTCYP1A1 | |
| SCHEMBL21801314 | 0.80 | CSNK2A2 (0.56) | CSNK2A2CSNK2BCSNK2A1TERTCYP1A1 | |
| SCHEMBL312312 | 0.77 | MAPT (0.71) | CSNK2A2CSNK2BCSNK2A1TDP1SMN1; SMN2 | |
| SCHEMBL21801102 | 0.77 | TERT (0.58) | CSNK2A2CSNK2BCSNK2A1TERTCYP1A1 | |
| SCHEMBL21801095 | 0.77 | TDP1 (0.64) | CSNK2A2CSNK2BCSNK2A1TERTCYP1A1 | |
| SCHEMBL31632272 | 0.74 | TNKS (0.53) | CSNK2A2CSNK2BCSNK2A1TERTCYP1A1 | |
| SCHEMBL21801127 | 0.74 | ABCB1 (0.38) | CSNK2A2CSNK2BCSNK2A1CYP1A1CYP1A2 | |
| SCHEMBL4649989 | 0.72 | CSNK2A2 (0.62) | CSNK2A2CSNK2BCSNK2A1TERTCYP1A1 | |
| SCHEMBL10305796 | 0.72 | TERT (0.66) | CSNK2A2CSNK2BCSNK2A1TERTCYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012390-B2 | Flavone compounds for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2024-06-18 | — | — | US | disclosed |
| CN-112601743-B | Flavone compounds for the treatment and prevention of hepatitis b virus diseases | 豪夫迈·罗氏有限公司 | 2023-12-19 | — | — | CN | disclosed |
| EP-3849966-B1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2023-10-25 | — | — | EP | disclosed |
| EP-3849966-B1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-20220363657-A1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2022-11-17 | — | — | US | disclosed |
| EP-3849966-A1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| CN-112601743-A | Flavone compounds for treating and preventing hepatitis B virus diseases | 豪夫迈·罗氏有限公司 | 2021-04-02 | — | — | CN | disclosed |
| WO-2020052774-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020052774-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020053249-A1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020053249-A1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012390-B2 | Flavone compounds for the treatment and prophylaxis of hepatitis B virus disease | PCNA, DNMT1, DNMT3B | CSNK2A2 3955/4885CSNK2B 3669/4885CSNK2A1 3802/4885 |
| US-20220363657-A1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | PCNA, DNMT1, DNMT3B | CSNK2A2 3955/4885CSNK2B 3669/4885CSNK2A1 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.